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Walking A Fine Line: Are SSRIs Really Depression
Wonder Drugs or Threats to Patient Safety?
Aisling V. O'Sullivan*
Introduction
In June 2001, the District Court of Wyoming decided Estate of
Tobin v. SmithKline Beecham Pharmaceuticals.' In Tobin, Donald
Schell, shot and killed his wife, daughter, granddaughter, and himself
while on the antidepressant Paxil.2 The jury found that Paxil was a
proximate cause of the deaths. This was a landmark case because it was
the first time a jury granted a verdict for plaintiffs in a selective serotonin
reuptake inhibitor (SSRI) antidepressant case. Prior to Tobin, hundreds
of similar cases against manufacturers of antidepressants were dismissed
or settled.5  In fact, before Tobin only two other cases against
antidepressant manufacturers actually went to trial, both of which
resulted in verdicts for the defendants.
6
This casenote examines the controversy that led up to the Food and
Drug Administration (FDA) requiring blackbox warnings on all SSRI
antidepressants alerting patients that suicidal and/or violent tendencies
could develop from ingesting the drugs. This note will analyze the
J.D. Candidate 2006, Pace University School of Law; B.A. Political Science, 2003,
Fordham University. The author would like to thank the Pace Law Review staff for their
editing assistance, and Cara Molloy for her invaluable comments on earlier drafts and her
friendship. The author is extremely grateful to her father, Patrick, for inspiring her to
attend law school, and her mother, Veronica, for her boundless love and encouragement.
Finally, the author is grateful to her boyfriend, Ryan, for his love and patience the last
three years and for his remarkable ability to always make her laugh.
1. 164 F. Supp. 2d 1278 (D. Wyo. 2001).
2. Id. at 1280.
3. Verdict Form, Estate of Tobin, 164 F. Supp. 2d 1278 (D. Wyo. 2001), available
at http://www.healyprozac.com/Trials/Tobin/Transcripts/6-6%Vendict.pdf (specifically,
the jury found the defendant SmithKline Beecham was 80% responsible for the plaintiffs'
injuries and that Donald Schell was 20% at fault).
4. Janet L. Holt, Documents from Paxil Case May Aid Plaintiffs Harmed by
Antidepressants, TRIAL, Sept. 2001, at 84.
5. Id.
6. Id.
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impact the Tobin decision had on this particular area of products liability
litigation and examine post Tobin cases to see whether this radical
decision impacted other courts. Finally, this note will examine the future
implications the new FDA requirements regarding warning labels on
SSRI drugs will have on current litigation for patients, doctors, and drug
manufacturers.
Part I of this article briefly defines SSRI drugs, how they treat
depression and how the popularity of these drugs rose in such a short
period of time. Part II of this article examines the initial studies linking
suicide and violence with SSRIs, discusses the only two cases to go to
trial before Tobin, and examines the "learned intermediary defense,"
which many manufacturers used as their defense in past litigation. Part
III discusses Tobin and whether the decision impacted subsequent cases.
Part IV discusses the new FDA warnings, examines the effect the
warnings will have on pending litigation in this area, outlines potential
tactics plaintiffs can take from Tobin, and analyzes how plaintiffs can
combine these tactics with the new FDA warnings in order to obtain
successful verdicts. Finally, Part V of the article reviews the potential
dilemmas facing the medical field, pharmaceutical companies, and users
(whose lives are improved by taking SSRIs) if plaintiffs are successful in
this area of products liability litigation.
I. Wonder Drugs: The Development of Selective Serotonin
Reuptake Inhibitors
Antidepressants, belonging to a class of drugs called selective
serotonin reuptake inhibitors (SSRIs), include Prozac (Fluoxetine),
Zoloft (Sertraline), Paxil (Paroxetine), Luvox (Fluvoxamine), and Celexa
(Citalopram).7 SSRJs work to block the absorption of serotonin, which is
a neurotransmitter that controls moods, into brain cells.8 By blocking the
absorption of serotonin, SSRIs allow individual neurons to communicate
with one another providing for more efficient transmission of electrical
signals to the brain, in turn promoting a feeling of well-being in patients. 9
7. Andrew E. Falsetti, Fluoxetine-Induced Suicidal Ideation: An Examination of the
Medical Literature, Case Law, and the Legal Liability of Drug Manufacturers, 57 FOOD
& DRUG L.J. 273, 274 (2002).
8. Sara Hoffman Jurand, Lawsuits Over Antidepressants Claim the Drug is Worse
than the Disease, TRIAL, Mar. 2003, at 14.
9. Id.; see also Angela M. Walker, R,: Take Two of These and Call Me in the
Morning; The Emergence of Litigation Regarding Psychotropic Medication in the United
States and Europe, 19 ARIZ. J. INT'L & COMP. L. 775, 776 (2002).
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From both a physician and patient perspective, SSRIs are more desirable
than other classes of antidepressants due to their "low side effect profile
and lack of toxicity in overdose."' This latter characteristic is especially
desirable for the treatment of depression." Even in the most extreme
overdose cases, SSRIs are rarely fatal.
12
Prozac was the first SSRI approved by the FDA in 1987.13 Prozac
became the world's most prescribed antidepressant and was heralded by
Newsweek as a "wonder drug" for depression.' 4 By 1997, Prozac was
the fifth most prescribed drug in the United States, and its success
spawned an influx of new SSRIs into the antidepressant market.'5
However, many family members of SSRI victims, who had suffered
through what they thought of as an SSRI related death, argued that the
drugs should not be treated as "wonder drugs."' 16 These family members
believed SSRIs had severe side effects that could cause suicidal and
violent behavior in patients that never before showed such tendencies.'
7
Akathisia can be a side effect of Prozac, Zoloft, and Paxil. 18 Akathisia
"is a neurological phenomenon characterized by intense internal
restlessness, agitation, aggression, and suicide attempts."' 9 Patients have
described akathisia as producing a desire to "jump out of their skin., 20
Harvard psychologist Dr. Jonathan Cole testified in a 2000 wrongful
death case that, "[t]he SSRI drugs, as a class, clearly have the potential to
cause, and in reasonable medical probability or certainty do cause,
akathisia in some patients... [which could] trigger or contribute to
violent or suicidal behavior.",
2 1
10. Walker, supra note 9, at 776.
11. Id.
12. Id.
13. Falsetti, supra note 7, at 273.
14. May L. Harris, Problems with Prozac: A Defective Product Responsible for
Criminal Behavior?, 10 J.CONTEMP. LEGAL IssuEs 359, 360 (1999).
15. Jurand, supra note 8, at 14.
16. Walker, supra note 9, at 776.
17. Jurand, supra note 8, at 14.
18. Id.
19. Id.
20. Id.
21. Id.
2006]
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II. The First Study Linking SSRIs to Violence, Early Defense Strategies
and Pre-Tobin Litigation
A. The First Study to Examine a Link Between SSRIs and
Violent Behavior
Harvard psychiatrist Martin H. Teicher's 1990 report on Prozac was
one of the first reports addressing how SSRIs could cause suicidal or
homicidal tendencies.22 Teicher studied six depressed patients, who prior
to their first dosage of Prozac did not exhibit suicidal or violent
behavior.23 Teicher was amazed at the results of the study.24 All of his
patients developed violent tendencies after twenty six days of taking
Prozac.25 Teicher explained that "[t]wo patients... tried to conceal their
suicidal feelings and impulses and to continue [Prozac] treatment,
believing that the drug would eventually enable them to successfully kill
themselves!, 26  Teicher further explained surprising outcomes of the
study as follows:
Two patients fantasized, for the first time, about killing themselves with a
gun..., and one patient... actually placed a loaded gun to her head. One
patient... needed to be physically restrained to prevent self-
mutilation .... [Another patient], who had no prior suicidal thoughts,
fantasized about killing himself in a gas explosion or a car crash.27
At that time, Teicher's article was criticized by many other
commentators for its small case sample size and the high doses of the
drug fluoxetine given to the patients.28 Today, many scientific studies
and commentators agree with Teicher's results and support the
22. Id.; see also John Alan Cohan, Psychiatric Ethics and Emerging Issues of
Psychopharmacology in the Treatment of Depression, 20 J. CONTEMP. HEALTH L. &
PoL'Y 115, 141 (2003) (citations omitted).
23. Cohan, supra note 22, at 141.
24. Id.
25. Id.
26. Id.
27. Id. at 141-42.
28. See Harris, supra note 14, at 362 n.33 (citing Maurizio Fava & Jerrold F.
Rosenbaum, Suicidality and Fluoxetine: Is There a Relationship?, 52 J. CLINICAL
PSYCHIATRY 108, 108-09 (1991) (which criticized Teicher for reporting an incidence rate
that by their estimation was "vastly distorted"); Richard A. Miller, Discussion of
Fluoxetine and Suicidal Tendencies, 147 AM. J. PSYCHIATRY 1571 (1990) (which
questioned the high doses of fluoxetine reported by Teicher and speculated that an
increase in observed suicidal preoccupation was due to severe akathisia)).
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proposition that SSRIs can cause suicidal ideation and homicidal
behavior.29
B. SSRI Manufacturers' Use of the "Learned Intermediary Defense"
and an Examination of Pre-Tobin Litigation
The two principal cases tried before Tobin, were Fentress v. Eli
Lilly & Company30 and Forsyth v. Eli Lilly & Company.31 In these early
cases, SSRI manufacturers usually employed a "learned intermediary
defense" against claims of inadequate warnings for potential side effects,
like suicide or violent behavior, on their drug labels. 32 In 1997, the
Restatement (Third) of Torts: Products Liability, promulgated the
defense providing that "a prescription drug or medical device is not
reasonably safe... if risks of harm are not provided to... prescribing
and other health care providers who are in a position to reduce the risks
of harm in accordance with the instructions or warnings. 33  The
Kentucky Supreme Court acknowledged three basic rationales behind
this defense in Larkin v. Pfizer Inc., 34 stating:
The first and best rationale is that the prescribing physician is in a superior
position to impart the warning and can provide an independent medical
decision as to whether use of the drug is appropriate for treatment of a
particular patient. . . . The second rationale for the rule is that
manufacturers lack effective means to communicate directly with each
patient.... [And] [t]he third rationale for the rule is that imposing a duty to
warn upon the manufacturer would unduly interfere with the physician-
patient relationship.
35
More generally, SSRI manufacturers have employed an overarching
defense by claiming that most patients taking SSRIs suffer from clinical
29. Cohan, supra note 22, at 142 n.144 (citing Eric W. Fine, M.D., Selective
Serotonin Reuptake Inhibitors (SSRIs) and Cases ofAlleged Related Violence, 23 AM. J.
FORENSIC PSYCHIATRY 5 (2003) (which noted that cases involving Prozac-induced suicide
and homicide cannot be ignored)).
30. See Walker, supra note 9, at 786; see also World Almanac Video, Landmark
Consumer Rights Trials: Prozac on Trial: Fentress v. Eli Lilly, 1, 2 (2001), available at
http://www.choicesvideo.net/guidebooks/WAV/LanCon-prozac.pdf.
31. Forsyth v. Eli Lilly & Co., 904 F. Supp. 1153 (D. Haw. 1995).
32. Andy Vickery, Changing Times for the Learned Intermediary Defense, TRIAL,
Sept. 2004, at 82.
33. Id.; see also RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 6(d)(2)
(1998).
34. Larkin v. Pfizer Inc., 153 S.W.3d 758 (Ky. 2004).
35. Id. at 763-64 (citations omitted).
2006]
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depression and therefore, already possess suicidal or violent tendencies. 36
To counter manufacturers' claims, families of victims and patients have
filed products liability suits against SSRI manufacturers for failure to
warn about the risk of increased suicidal or violent behavior.37 Also,
family members have called for the FDA to clamp down on the drug
makers and require warning labels on the drug bottles. 38 Over the years,
these lawsuits have ended in settlements or summary judgments in favor
of manufacturers.39  Summary judgments were common because
plaintiffs lacked evidence to establish that the maker of the SSRI knew or
potentially knew that the antidepressant was dangerous.4 °
The first lawsuit claiming that Prozac specifically caused violent
behavior was the 1987 case, Fentress v. Eli Lilly & Company.4' In
Fentress, Joseph R.Wesbecker shot and killed eight people, injured
twelve others and then committed suicide at his workplace.42 Wesbecker
had been taking Prozac prior to the shootings.43 The jury found for Eli
Lilly.44 The Fentress verdict suggested that "the user [was] responsible
for his own actions when the actions [were] consistent with [the user's]
behavior prior to taking the medication. ' 45  Therefore, the Fentress
decision does not address whether
while taking psychotropic medication, one may act in a way inconsistent
with [their] previous normal behavior ... [and] [t]his verdict leaves the
door wide open for cases in which a Prozac user, who had never exhibited
signs of violence before treatment with the drug, begins to act violently
while taking Prozac.
4 6
In Forsyth v. Eli Lilly & Company, William Forsyth killed his wife
and then himself.47 The verdict was for Eli Lilly even though Forsyth
killed his wife and then himself after being on Prozac for only two
36. Jurand, supra note 8, at 14.
37. Holt, supra note 4, at 86.
38. Id.
39. Id. at 84.
40. Id.
41. Walker, supra note 9, at 786; see generally World Almanac Video, Landmark
Consumer Rights Trials: Prozac on Trial Fentress v. Eli Lilly 1, 2 (2001), available at
http://www.choicesvideo.net/guidebooks/WAV/LanCon-prozac.pdf.
42. Walker, supra note 9, at 786.
43. Id.
44. Id.
45. Id. at 788.
46. Id.
47. Forsyth v. Eli Lilly & Co., 904 F. Supp. 1153, 1155 (D. Haw. 1995).
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weeks.48 Before the verdict in Forsyth, the plaintiffs still hoped they
could win at trial if they presented evidence that a user had no previous
violent or suicidal tendency, which would imply that the SSRI caused the
violence. This argument was suggested in Fentress, but the Forsyth
verdict seemed to close the door on any chance for the plaintiffs to win
using that argument. Again, Eli Lilly's attorney claimed the victim's
depression caused the killings, not Prozac, stating "[t]he case is about a
good drug and a very bad, powerful disease. '49
A turning point for plaintiffs bringing suits against SSRI
manufacturers came when the United States District Court of Wyoming
decided Estate of Tobin v. SmithKline Beecham Pharmaceuticals. The
jury found for the plaintiffs, specifically holding that Paxil could cause
some users to commit suicide and/or homicide.50
III. Examining the Case of Tobin v. SmithKline Beecham
A. Tobin v. SmithKline Beecham: The Factual Background and
Opposing Theories
In Tobin, the plaintiffs presented several products liability claims;
specifically, negligent failure to warn, negligent misrepresentation, and
negligent failure to test and investigate. 51 As a matter of law, the court
dismissed the plaintiffs' claim for negligent misrepresentation.52
Plaintiffs alleged at trial that Donald Schell, shot and killed his wife,
his daughter, his granddaughter, and himself, as a result of taking Paxil.53
At the time of the shootings, Donald Schell had been taking Paxil for two
days and ingested only two doses of the drug.54 Schell had fought with at
least five bouts of depression and in the past had not followed the advice
of three psychiatrists about his medication. 55  At trial, the plaintiffs'
attorneys argued that the defendant failed to provide adequate warning
48. Id. at 1155, 1161.
49. Harris, supra note 14, at 360.
50. See Verdict Form, supra note 3.
51. Estate of Tobin v. SmithKline Beecham Pharms., 164 F. Supp. 2d 1278, 1280
(D. Wyo. 2001).
52. Id. ("the [c]ourt dismissed as a matter of law the plaintiffs' claim for negligent
misrepresentation under § 402B of the Restatement of Torts.").
53. Id.
54. Falsetti, supra note 7, at 287.
55. Id.
2006]
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labels about possible violent reactions or suicide attempts from ingesting
the drug.56 Also, the plaintiffs argued that SmithKline Beecham did not
adequately test Paxil to determine if it caused violence and/or suicide.57
Therefore, they argued, the company misled the public, its customers,
and doctors.58 The plaintiffs' theory was that Schell was dealing with
akathisia, which led to his violent reaction towards his family and
himself.59 The defense, on the other hand, argued Schell's ingestion of
one tablet of Paxil daily for two days did not cause him to commit
murder and suicide, but that his violent reaction was caused by his
clinical depression.60
B. Arguments at Trial, the Battle Over Expert Testimony, and the Verdict
To prove their theory, the defense had a three part strategy: (1) to
use scientific evidence to show that SSRIs help millions of people; (2) to
emphasize that depression is a dangerous disease that can cause
abnormal behavior including violence and suicide; and (3) to show that
Schell had previous violent or suicidal tendencies. 61 To counter the
defense's scientific evidence and experts, plaintiffs' lawyers intended to
use their own experts to testify that SSRIs can make patients violent
and/or suicidal.62 During trial, the defense made a motion to exclude or
limit the testimony of plaintiffs' experts, Dr. Healy and Dr.
Maltsburger.63 The court denied the motion concluding that the plaintiffs
demonstrated the reliability and the relevance of the proposed testimony
of Dr. Healy and Dr. Maltsburger.64
56. Falsetti, supra note 7, at 287.
57. Id.; see also Estate of Tobin, 164 F. Supp. 2d at 1280.
58. See Cohan, supra note 22, at 154.
59. Falsetti, supra note 7, at 287; see also Estate of Tobin, 164 F. Supp. 2d at 1284.
60. Cohan, supra note 22, at 154.
61. Falsetti, supra note 7, at 287.
62. Id.
63. Estate of Tobin v. SmithKline Beecham Pharms., No. 00-CV-0025-Bea (D.
Wyo. May 8, 2001) (order denying defendant's motion to exclude or limit the testimony
of plaintiffs' witnesses), available at http://www.justiceseekers.com/files/NLPP00000
/042.pdf [hereinafter Tobin Order]. The defense argued that the court should exclude or
severely limit the testimony of Dr. Healy and Dr. Maltsburger for three reasons: (1) that
the doctors are not properly qualified to offer expert testimony under FRE Rule 702; (2)
that the proposed opinion testimony of the doctors is not reliable since research involving
SSRIs other than Paxil cannot be used to establish the effects of Paxil; and (3) the
doctors' methodologies are unreliable because they have not been published and they are
driven by litigation. Id. at 5, 6.
64. Id. at 3, 4.
[Vol. 26:549
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At trial, the plaintiffs' attorneys offered Dr. Healy's expert
testimony to prove the theory that Paxil can generally cause suicidal
ideation. The plaintiffs used Dr. Healy's testimony to establish that Paxil
can cause some patients to become homicidal or suicidal, "by inducing
either: (1) extreme anguish, akathisia, or agitation; (2) psychotic
decompensation; or (3) emotional blunting. '65 Dr. Healy testified that
SSRls can "produce a state of affairs which make an individual who may
not have been likely to commit suicide before taking the pill, more likely
to do so while on a course of treatment., 66 Furthermore, Dr. Healy
testified that, "Paxil is an SSRI that [in his] experience can produce these
problems. There are a number of studies in the literature supporting this
position. There is also an extensive literature on SSRIs in respect to
these possibilities. 67  Dr. Healy based his conclusions of general
causation on "his own clinical experience, his review of healthy
volunteer data gathered by the defendant, and published scientific
works., 68 Finally, Dr. Healy testified to specific causation, stating, "I
believe that if Mr. Schell didn't have the Paxil that he had been given
that he would be alive today and so would his family., 69 Dr. Healy
based his statements on his review of Schell's medical records and
Schell's anxiety problems when he was on Prozac.7 °
Dr. Malsburger testified at trial to prove that Schell's use of Paxil
caused the killings and his suicide.71 The most compelling part of his
testimony concerned the dangerous consequences that can develop from
prescribing SSRls to patients who already demonstrate akathisic
symptoms. 72 Dr. Malsburger testified as follows:
When a patient has a hypomanic history (Mr. Schell appears to have had
none) or already exhibits akathisic symptoms (Mr. Schell did), SSRI
compounds should not be prescribed because they have the potential to
make the anxiety much worse, indeed, to make it unbearable. There are
credible reports of patients becoming suicidal and homicidal when thrown
into intolerable states of anguish by prescription of these drugs .... Already
anxious, his mind speeding, and sleepless, when given an SSRI in 1998,
65. Id. at 3.
66. Id.
67. Id.
68. Estate of Tobin v. SmithKline Beecham Pharms., 164 F. Supp. 2d 1278, 1283
(D. Wyo. 2001).
69. Id. at 1284.
70. Id.
71. See Tobin Motion, supra note 63, at 4.
72. Id.
2006]
9
PACE LAWREVIEW
[Schell] quickly became violent and killed his family and himself.... In
this case, I can identify only one factor which triggered the murders and
subsequent suicide; Paxil .... Though we lack details of what exactly Mr.
Schell's mental state was on that fatal night, it is clear to me that it was
Paxil that drove him out of control.
73
The plaintiffs presented evidence that another SSRI manufacturer
had knowledge that its products could cause violent and suicidal
tendencies in users. The plaintiffs introduced evidence that Eli Lilly, the
makers of Prozac, had initially included a statement in Prozac's
packaging warning, "mania and psychosis may be precipitated in
susceptible patients by antidepressant therapy., 74 However, Eli Lilly did
not include the warning in the final packaging for Prozac.75 Also, Eli
Lilly failed to inform the FDA that Germany's Bundes Gesundheits Amt
(Germany's version of the FDA) had required a label that warned users
of an increased risk of suicide on Prozac before the agency would
approve the drug for distribution in Germany.7 6
Finally, the plaintiffs' attorneys introduced internal company
documents from SmithKline Beecham establishing the company's
awareness that a small number of patients could become agitated or
violent due to ingestion of Paxil.77  In addition, a former SmithKline
Beecham employee testified that Paxil should be "titrated" (the patient
should be started on a low dose and increased over time).7 s Finally,
plaintiffs' attorneys argued that Schell's doctor, Dr. Patel, would have
followed a warning label and explained to Schell the possible side effects
of taking Paxil. 79 Dr. Patel testified that, "[I] would have liked to have
had this information before prescribing Paxil for [Schell] and that it
would have affected [my] treatment decisions. ,80 In closing, the
plaintiffs' attorneys left the jury to answer, "whether or not the
depression was exacerbated or triggered by [Paxil and] ... flipped it into
something far worse than ordinary depression."
8
'
The jury deliberated for five hours and came back with a verdict for
73. Id.
74. Jurand, supra note 8, at 16.
75. Id.
76. Id.; see also Sara Hoffman Jurand, New Data Show Paxil May Increase Suicide
Risk in Children, TRLAL, Oct. 2003, at 75, 75-77.
77. Falsetti, supra note 7, at 287.
78. Vickery, supra note 32, at 85.
79. Id.
80. Id.
81. Falsetti, supra note 7, at 287.
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the plaintiffs, finding SmithKline Beecham 80% liable for the killings
and the suicide and Schell 20% at fault.82 The court entered a judgment
in excess of seven million dollars for the plaintiffs.83 After the verdict,
SmithKline Beecham claimed that "it was clear from the facts, science
and common sense ... [that] escalating depression caused this. 8 4 The
company also argued that only two doses of Paxil could not have lead to
85Schell's violent reaction.
Subsequently, SmithKline Beecham filed a motion for judgment as
a matter of law, or in the alternative, for a new trial.86 SmithKline
Beecham contended there was no reliable scientific evidence to support
the conclusions that Paxil can cause suicide and homicide.87 Also, the
defense argued there was no evidence that the absence of warnings
proximately caused the murders and suicide in this case.88 The court
ordered that the judgment stand.89 Specifically, the court concluded both
of the plaintiffs' experts were qualified and based their conclusions on
sound scientific analysis. 90 The court ruled that Dr. Patel's testimony
was sufficient to allow a reasonable jury to conclude that if Paxil
contained a warning label about homicide and suicide, he may not have
prescribed the drug or would have monitored Schell differently.91
Therefore, it was reasonable for the jury to conclude that the defendant's
product contained an inadequate or improper warning.
92
Commentators predicted that this case would have severe legal
ramifications for the other SSRI manufacturers since all of these drugs
have similar side effects. Thus, other SSRI antidepressants could be
"implicated by association."93 Judge Brennan, who delivered the opinion
of the district court, emphasized that "[t]he list of side effects for all of
the drugs in the class overlaps heavily .... The general designation of
these drugs as SSRIs... refers to a common understanding that broadly
82. See Verdict Form, supra note 3, at 2.
83. Id. at 3.
84. Falsetti, supra note 7, at 287.
85. Id.
86. Estate of Tobin v. SmithKline Beecham Pharms., 164 F. Supp. 2d 1278, 1280
(D. Wyo. 2001).
87. Id. at 1280.
88. Id. at 1281.
89. Id. at 1290.
90. Id. at 1283-87.
91. Id. at 1287.
92. Id.
93. Cohan, supra note 22, at 154.
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11
PACE LAWREVIEW
speaking the drugs are similar- there may be differences but there is
broad overlap. 94 Attorney George Murgatroyd, who has handled several
cases dealing with Paxil, was quoted after the Tobin decision stating that
"the Tobin victory will make it easier for attorneys bringing
antidepressant cases, primarily because company documents showing
that Paxil could cause serious side effects were made public." 95
However, many courts were reluctant to follow the Tobin decision.96
The reluctance stemmed from the lack of general consensus among the
FDA and the medical community about suicidal and homicidal
tendencies as potential side effects of SSRIs.
97
C. The Reluctance of Courts to Follow Tobin: An Analysis of Three
Subsequent and Similar Cases
Smith v. Pfizer was decided three days after Tobin was affirmed.98
In this case, the decedent, Daryl Dempsay, stabbed his wife and two
children, and then committed suicide. 99 The plaintiffs' claims against
Pfizer were for failure to test and to warn, and marketing defects and
misrepresentations. 100 The decedent's wife claimed that her husband's
ingestion of Zoloft had caused his violent outbreak. 10 1 In response, the
defense filed a motion for summary judgment alleging that plaintiffs
failed to establish general causation, inadequate testing or warnings, and
wanted to exclude testimony from plaintiffs' expert witness.1
0 2
Specifically, the defense attacked the plaintiffs' only expert witness, Dr.
Maltsberger, claiming that he was not qualified to give his opinion on a
potential causal link between Zoloft, akathisia, and violent behavior.1
0 3
The plaintiffs tried to counter the defense's attack on general
causation by presenting the testimony from Tobin, and explaining that
Dr. Maltsberger was allowed to testify as an expert witness in that
94. Id. at 156.
95. Holt, supra note 4, at 84.
96. See Blanchard v. Eli Lilly & Co., 207 F. Supp. 2d 308 (D. Vt. 2002); see also
Smith v. Pfizer Inc., No. 98-4156-CM, 2001 WL 968369 (D. Kan. 2001); Cloud v. Pfizer
Inc., 198 F. Supp. 2d 1118 (D. Ariz. 2001).
97. See Blanchard, 207 F. Supp. 2d at 318-22.
98. Smith, 2001 WL 968369 at *1.
99. Id.
100. Id.
101. Id.
102. Id. at *9.
103. Id. at *6, *7.
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case. 10 4 However, the Smith court distinguished Tobin explaining that
the Tobin court allowed expert testimony relating to general causation
based on the plaintiffs' other expert, Dr. Healy, and not from Dr.
Maltsberger 0 5 The Smith court explained that Dr. Healy was qualified
to give an opinion on a connection between Zoloft and violence to
establish general causation. 0 6  The Smith court concluded that Dr.
Maltsberger was not qualified to testify on general causation, but allowed
Dr. Maltsberger to testify on specific causation.'0 7 Since the plaintiffs
had no other expert witnesses at trial to testify to general causation, the
court granted the defense's motion for summary judgment.10 8
The case Cloud v. Pfizer was decided three months after Tobin. 09
The decedent, Darren Baskins, committed suicide in August of 1997.'10
Baskins had originally been prescribed Zoloft for minor depression in
February of 1996.11 Baskins and his wife were having marital problems
and his wife had threatened to leave him prior to his hospitalization in
August 1997.1 12 Evidence showed that the week before Baskins' death
his mood had altered and a counselor had diagnosed him as suicidal.'
3
Baskins was admitted into a hospital before his death and the medical
staff testified at trial that Baskins was not displaying akathisia. 1 4 Three
days after being released from the hospital, Baskins hung himself at his
home.' Baskins' widow brought a products liability and negligence
action against Pfizer, the manufacturer of Zoloft, for alleged failure to
warn and/or provide proper instructions regarding the potential side-
effect of suicide."l
6
At trial, Pfizer made a motion to exclude the expert testimony of
plaintiffs' witness, Dr. Edwin E. Johnstone.' ' Surprisingly, the plaintiffs
used Dr. Johnstone even though he testified that the articles upon which
104. Id. at *8.
105. Id.
106. Id.
107. Id. at *9.
108. Id. at *12.
109. Cloud v. Pfizer, 198 F. Supp. 2d 1118, 1118 (D. Ariz. 2001).
110. Id. at 1121.
111. Id. at 1121,1127.
112. Id. at 1127.
113. Id.
114. Id. at 1128.
115. Id.
116. Id. at 1121.
117. Id. at 1128.
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he relied on for general causation were only "strongly suggestive" of the
fact that Zoloft causes suicide." 8 Pfizer argued that Dr. Johnstone's
testimony should be excluded because he failed to satisfy both the
reliability and fitness requirements under the Daubert v. Merrell Dow
Pharmaceuticals test." 9 The Cloud court decided that Dr. Johnstone's
testimony should be excluded from the trial and as a result granted
summary judgment in favor of Pfizer. 20 The Cloud court noted that Dr.
Johnstone had no clinical experience with any patient committing suicide
while on Zoloft, had not published articles, given any testimony, or
communicated to scientific organizations that SSRIs cause suicide.'
21
The Cloud court explained that Dr. Johnstone was not qualified to testify
about a general causal link between Zoloft and suicide because he relied
upon Dr. Healy's analysis of Pfizer in clinical trials and not his own
study. 22 Also, the Cloud court ruled Dr. Johnstone was not qualified to
testify on specific causation because the doctor came to his conclusions
that Zoloft caused Baskins' suicide before the doctor reviewed all of
Baskins' medical records. 23  Also, the Cloud court noted that Dr.
Johnstone failed to fully explore other potential causes of Baskins'
suicide including his alcohol use, family problems, and the diet pill
ephedrine. 1
24
Finally, Blanchard v. Eli Lilly & Company followed the pattern of
the other post-Tobin decisions discussed above by granted Eli Lilly's
motion for summary judgment. 125 In this case, the decedent Elvira
Espinoza shot and killed her two children and then herself.' 26 At the time
of her death, the decedent was taking Prozac, which she had been
prescribed some years prior for depression. 127 The decedent's dosage for
Prozac had been increased before her death, but she was also known to
adjust her own dosage randomly. 28 The plaintiffs, decedent's parents
and ex-husband, brought a products liability case against Eli Lilly,
claiming that the decedent's ingestion of Prozac caused her to kill her
118. Id. at 1133.
119. Id. at 1128; see also Daubert v. Merrell Dow Pharms., 509 U.S. 579 (1993).
120. Cloud, 198 F. Supp. 2d at 1139.
121. Id. at 1131.
122. ld. at 1134.
123. Id. at 1135-36.
124. Id. at 1136.
125. Blanchard v. Eli Lilly & Co., 207 F. Supp. 2d 308, 311 (D. Vt. 2002).
126. Id.
127. Id.
128. Id.
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children and herself.129 There was evidence at trial that the decedent was
diagnosed with major depression and dependent personality disorder. 130
She also had several major stress factors in her life including: (1) the
breakup of her marriage; (2) poverty; (3) single motherhood; (4) her
belief that her ex-husband had abandoned their children; (5) her
children's behavioral problems; (6) the threat of losing custody; (7) her
own academic problems in nursing school; (8) dissatisfaction with her
appearance; (9) and absence of a love life.13'
The plaintiffs relied on testimony from Dr. Maltsberger to establish
their products liability claims. 32 The doctor reviewed extensive material
about the decedent's life, and concluded that Prozac was a contributing
cause of decedent's death, but he did not specifically address a causal
connection between the decedent's ingestion of Prozac and the deaths of
her children.' 3 3 Eli Lilly argued that the doctor's testimony failed to
establish general and specific causation and moved for summary
judgment. 34 The court concluded that the doctor's testimony failed to
meet the Daubert standard. 135 The plaintiffs failed to elicit testimony
from the doctor that his opinion of a link between SSRIs and suicide, led
to a conclusion that in the decedent's case, Prozac caused her violent
behavior. 36 However, the court stressed, "that it is not holding that Dr.
Maltsberger's methods cannot provide a reliable basis for an expert
opinion on causation, but that in this particular case the information upon
which Dr. Maltsberger based his opinion could not reliably determine the
cause of this particular double homicide-suicide.' 37 Also, there was no
evidence that the decedent was suffering from akathisic symptoms and
the plaintiffs failed to show that the doctor had any data (from his
clinical experience or other scientific literature) that SSRIs trigger
suicidal thoughts or violence in people who are not at the same time
experiencing akathisia, mania, hypomania, or disinhibition.
138
129. Id. at311.
130. Id. at 312.
131. Id.
132. Id. at 313.
133. Id. at313 n.3.
134. Id. at315.
135. Id. at 319-20.
136. Id. at 320.
137. Id.
138. Id.
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D. Justifying the Different Outcomes in Smith, Cloud, Blanchard, and
Tobin
The different outcomes in Smith, Cloud and Blanchard from Tobin
can be explained by analyzing the medical histories of the decedents and
the varied expert testimony given at each trial. In Smith, the decedent
had been abused as a child, and had a long history of depression and drug
and alcohol abuse. 139 In addition, the decedent (Dempsay) had been in
jail on multiple occasions, and spent a total of five years in jail for
offenses related to alcohol and drugs. 140 Finally, the decedent was also
on a high dosage of the anxiety medication Xanax when he killed
himself.14  In Tobin, however, the decedent (Schell) did not have a
violent past, had no obvious marital problems, and seemed to adore his
children and grandchildren. 142 Also, Schell had a bad reaction to an
SSRI in the past.143 Finally, in Tobin, the plaintiffs' attorneys presented
a stronger case against SmithKline Beecham than the case presented
against Pfizer in Smith. In Tobin, the court heard the expert testimony of
both Dr. Healy and Dr. Maltsberger, as opposed to just the testimony
from Dr. Maltsberger in Smith. These differences between the two cases
justify the ruling in favor of Pfizer in Smith, since there was
overwhelming evidence in Smith that the decedent's depression was the
cause of his violent behavior and not the SSRI.
The different result in Cloud can similarly be explained since the
decedent (Baskins) had many additional stress factors that could have
caused him to commit suicide. Again, there was no indication in Tobin
that the decedent suffered from anything but minor depression. In Smith,
Cloud and Blanchard, the decedents suffered from major depression and
had other stress triggers in their lives, all of which could have caused
their violent behavior.
Finally, in Blanchard, the court explained why the case was
distinguishable from Tobin, requiring a verdict for Eli Lilly, even though
Dr. Maltsberger was an expert witness in both. 144 The major difference
in Dr. Maltsberger's testimony was that the doctor could not expressly
139. Smith v. Pfizer Inc., No. 98-4156-CM, 2001 WL 968369, *2 (D. Kan. 2001).
140. Id.
141. Id.
142. Holt, supra note 4, at 84.
143. Estate of Tobin v. SmithKline Beecham Pharms., 164 F. Supp. 2d 1278, 1284
(D. Wyo. 2001).
144. Blanchard v. Eli Lilly & Co., 207 F. Supp. 2d 308, 321 n.6 (D. Vt. 2002).
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state that Prozac caused the decedent Espinoza's violent behavior. 145
This is in contrast to Maltsberger's testimony in Tobin, where he
specifically linked Paxil to Schell's violent behavior.1
46
IV. Emerging Developments for SSRI Drugs, the FDA Warnings, and
Strategies for Litigation
A. The FDA Steps In: Ordering Blackbox Warnings For All SSRI Drugs
Prior to any public action taken by the FDA on SSRI drugs, the
United Kingdom's Department of Health reviewed the potential link
between suicide and SSRIs. 147  In late 2003, the United Kingdom's
Department of Health publicly ordered that children younger than
eighteen should not be prescribed SSRIs (except Prozac), because of the
drugs' link to suicide. 48  In June 2003, the FDA privately began
reviewing whether SSRI drugs raise the risk of suicide in children and
teenagers. 149 The FDA solicited researchers from Columbia University
to review different studies indicating a risk of increased suicidal
tendencies when taking SSRI drugs.' 50 The FDA asked the researchers
to develop their own study to guide what actions the agency should take
in this area.1 51  In March, before the study was complete, the FDA
announced that it was "asking" the manufacturers of ten antidepressants
to put stronger suicide warnings on the package inserts of their drugs, "to
encourage close observation for worsening depression or the emergence
of suicidal thinking and behavior in both adult and pediatric patients
being treated with [SSRIs].' 52
The requested warnings would also advise and alert doctors to look
145. Id. at313 n.3.
146. Tobin Motion, supra note 63, at 4.
147. Injuryboard.com, Antidepressants and Other Psychiatric Drugs, http://www.
injuryboard.com/view.cfniTopic=375 (last visited Mar. 29, 2006).
148. Id.
149. FDA Talk Paper, FDA Issues Public Health Advisory on Cautions for Use of
Antidepressants in Adults and Children, Mar. 22, 2004, http://www.fda.gov/bbs
/topics/ANSWERS/2004/ANS01283.html.
150. FDA Talk Paper, FDA Updates Its Review of Antidepressant Drugs in
Children, Aug. 20, 2004, http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01306.
html.
151. Id.
152. FDA, Questions and Answers on Antidepressant Use in Children, Adolescents,
and Adults, http://www.fda.gov/cder/drug/antidepressants/Q&A-antidepressants.htm
(last visited Mar. 29, 2006).
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for symptoms associated with depression and suicide in their patients. 153
The FDA asked the manufacturers of ten SSRI drugs (including Prozac,
Zoloft, Paxil, Luvox, Celexa, Lexapro, Wellbutrin, Effexor, Serzone, and
Remeron) to place warnings on their inserts. 154  However, the FDA
repeatedly cautioned that it had not established a causal link between
increased suicidal tendencies and ingestion of SSRI drugs.'55 The
agency explained it was still reviewing the possibility of a link and
planned to hold a public meeting at the end of the summer to announce
its final analysis. 156 Prior to the March announcement, the FDA was
under a congressional investigation for prohibiting Dr. Andrew
Mosholder from testifying before an FDA advisory panel.' 57 Mosholder
was an epidemiologist for the FDA and the first FDA official to find and
discuss the link between suicide and SSRI drugs.'58
In August 2004, the FDA released a "talk paper" updating the
public and the medical community on their review of SSRI drugs, the
Columbia study, and the progress made after the March
announcement. 59 The FDA stated that since the March announcement
seven manufacturers added the warning language to their products, and
three other makers had agreed to adopt the language. 60 In addition, the
Columbia study had presented "data suggestive of an increased risk of
suicidality for some of these drugs, but there remain inconsistencies in
the results, both across trials for individual drugs and across drugs."'
161
The FDA concluded that because of these inconsistencies "an overall
interpretation of these findings represents a substantial challenge."'
' 62
The FDA was being cautious about announcing any finding since "as a
public health agency, [we] must weigh the possibility of an increased risk
of suicidality in young patients taking these drugs against the known risk
of suicide in patients whose depression goes untreated."'163 The agency
153. Id.
154. Id.
155. Id.
156. Id.
157. CBSNews.com, Antidepressant Warnings Weighed, Sept. 13, 2004, http://
www.cbsnews.com/stories/2004/09/14/health/printable643433.shtml.
158. Id.
159. FDA Talk Paper, FDA Updates its Review of Antidepressant Drugs in
Children, Aug. 20, 2004, http://www.fda.gov/bbs/topics/ANSWERS/2004/ANSO1306.
html.
160. Id.
161. Id.
162. Id.
163. Id.
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also indicated it would hold a public Advisory Committee meeting in
September with the Psychopharmacologic Drugs and the Pediatric
Advisory Committees about the study to discuss whether they should
require strong warning labels on SSRI drugs. 164
At the September hearing, Dr. Mosholder was finally allowed to
testify about the link he found between suicide and SSRIs.'65 The FDA's
director of neuropharmacological drug products, Dr. Russell Katz,
explained why the FDA did not allow Dr. Mosholder to testify earlier. 66
Katz testified that there were errors in early studies, which were
inconclusive on the safety of the drugs, and therefore, too dangerous for
the agency to announce. 167 Also, 73 family members who lost loved
ones taking SSRIs testified at the hearing. 168 The family members called
for the FDA to order manufacturers to place strong warning labels on the
outside of the drugs' packaging. 169 Coinciding with the FDA's
September hearing, Congress continued to investigate whether the FDA
was covering up any information on the links of suicide and SSRIs, and
if the agency was silencing employees who were aware of the risks. 70
The family members who testified at the September hearing got
their wish in October of 2004, when the FDA ordered that all SSRI
antidepressant drugs carry a black box warning on the outside of the
packaging, which is the agency's strongest safety alert. 17 1 The warning
will alert users and doctors that there is a link between ingesting the
drugs and increased suicidal thoughts and behavior among teens and
children who are prescribed the drugs. 172 The FDA also will create a
medication guide for patients that will alert them of the risk, since the
black box warnings are often only seen by doctors. 73 The guide will
alert parents about the warning signs for suicidal symptoms in their
children that could come within the first month of use or a change in
164. FDA Talk Paper, FDA Updates its Review of Antidepressant Drugs in
Children, Aug. 20, 2004, http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01306.
html.
165. CBSNEWS.com, Antidepressant Warnings Weighed, Sept. 13, 2004,
http://www.cbsnews.com/stories/2004/09/14/health/printable643433.html.
166. Id.
167. Id.
168. Id.
169. Id.
170. Id.
171. CBSNEWS.com, FDA Orders Antidepressant Warning, Oct. 15, 2004,
http://www.cbsnews.com/stories/2004/08/O4/health/printable63409.shtml.
172. Id.
173. Id.
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dosage. 174 The warning signs "include worsening depression, agitation,
irritability, and unusual changes in behavior."'175 Dr. Lester Crawford,
the acting FDA commissioner, spoke about the balance the agency was
trying to strike with warnings about the drugs against the benefit of
treating children with SSRls. 17 6  Crawford stated that the "[FDA]
continues to believe, however, that these drugs provide significant
benefits for pediatric patients when used appropriately" and the new
warning label alerts patients to the "risk of suicidality and encourages
prescribers to balance this risk with clinical need."' 177  At the
announcement for the black box warnings, the FDA released a finding
from the Columbia University study, which found that 2-3% of children
using SSRI drugs had increased suicidal thoughts.
78
B. Outlining Tactics for Litigation: Can Plaintiffs Succeed by
Combining Strategies from Tobin, the New FDA Warnings, and Released
Documents From SSRI Makers?
With mandatory black box warnings on suicidal and violent
tendencies as side effects of SSRIs and developing allegations that some
SSRI makers had prior knowledge of these dangers, there is new hope
for plaintiffs seeking judgments against SSRI manufacturers. 79 This
new hope gained momentum when New York Attorney General Eliot
Spitzer filed a lawsuit, after the FDA blackbox announcement, alleging
that GlaxoSmithKline, the makers of Paxil, committed fraud by
withholding "negative information and misrepresenting data on
prescribing its antidepressant Paxil to children."' 180 The suit also alleged
that Glaxo "suppressed four studies that failed to demonstrate the drug
was effective in treating children and adolescents and that suggested a
174. Id.
175. Id.
176. Id.
177. MSN.com, New Warning Label Ordered for Antidepressants, Oct. 15, 2004,
http://www.msnbc.msn.com/id/6254504/print/1/displaymode/1098/.
178. CBSNEWS.com, FDA Orders Antidepressant Warning, Oct. 15, 2004,
http://www.cbsnews.com/stories/2004/08/04/health/printable634089.shtml.
179. Reuters, Glaxo Faces Lawsuits From U.S. Parents Over Paxil, available at
http://www.antidepressantsfacts.com/2004-09-06-GSK-lawsuits-US-parents-paxil.htm
(last visited Mar. 29, 2006).
180. CBSNEWS.com, NY State Sues Drug Giant, June 3, 2004, http://www.
cbsnews.com/stories/2004/08/26/health/printable638707.shtml.
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possible increase in suicidal thinking and acts."' 181 Also, the suit alleged
that an internal document from 1999 showed that Glaxo intended to
"manage the dissemination of data in order to minimize any potential
negative commercial impact."' 82  Glaxo initially denied any
wrongdoing, 183 but then agreed to settle the lawsuit with the State of New
York. 184 Glaxo agreed to a scheduled release of internal negative data on
the safety and effectiveness of Paxil and agreed to pay $2.5 million to
New York State. 185 The negative data will be posted on Glaxo's website
by the end of 2005 and will include summaries of all of Glaxo's medical
studies on Paxil since December 2000.186 Glaxo's spokesperson Nancy
Pekarek stated, "[Glaxo is] choosing to settle this basically to avoid the
high cost and time of protracted litigation." Spitzer's health care bureau
chief responded to the settlement by stating, "[t]he immediate impact is
sending a signal to the other pharmaceutical manufacturers that this is the
new standard with regard to disclosure of clinical studies. We will
continue to do that until we feel this industry as a whole has stopped this
practice."'' 87 In response to this settlement, many families with similar
claims filed lawsuits against GlaxoSmithKline. 88 The suits are alleging
that Glaxo suppressed data that showed the drug increased suicidal
tendencies in young people. 1
89
Eli Lilly has also been accused of suppressing negative data.' 90 As
early as fifteen years ago, Eli Lilly possessed data showing users of
Prozac were far more likely to attempt suicide and show hostility than
were patients on other SSRI drugs. 191 The report shows that Eli Lilly
was attempting to minimize public awareness of these negative affects.' 92
The document included the following: (1) 3.7% of patients attempted
181. Id.
182. Id.
183. Id.
184. CBSNEWS.com, Glaxo Settles Paxil Lawsuit, Aug. 24, 2004, http://www.
cbsnews.com/stories/2004/06/03/health/printable620815.shtml.
185. Id.
186. Id.
187. Id.
188. Reuters, Glaxo Faces Lawsuits From U.S. Parents Over Paxil, available at
http://www.antidepressantsfacts.com/2004-09-06-GSK-lawsuits-US-parents-paxil.htm
(last visited Mar. 29, 2006).
189. Id.
190. Tom Watkins, Papers Indicate Firm Knew Possible Prozac Suicide Risk, Jan.
3, 2005, http://www.cnn.com/2005/HEALTH/01/03/prozac.documents/.
191. Id.
192. Id.
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suicide while on Prozac (a rate more then twelve times cited for any of
the other four commonly used SSRIs), (2) 2.3% of the users suffered
psychotic depression while on the drug (more then double the next
highest rate of patients using another antidepressant), (3) 1.6% of
patients reported incidents of hostility (more then double the rate for the
other top four manufacturers), and (4) 0.8% of users of Prozac reported
causing an intentional injury (eight times the rate than other SSRIs).'93
Also, it was documented that Prozac may produce nervousness, anxiety,
agitation, or insomnia in 19% of users and sedation in 13% of users.
194
The authors of this report suggested ways to explain this data,
explaining that "several suggestions may be helpful in presenting this
information to physicians... including emphasizing that more patients
on another class of antidepressants stopped taking their drugs than did
those on Prozac."' 9 5  This report purportedly reappeared after being
reported missing during the Fentress case.196 Eli Lilly posted a statement
on its website stating "[t]o our knowledge, there has never been any
allegation of missing documents from the Wesbecker [Fentress] trial or
any other trial involving Lilly."' 9 Subsequently, the FDA received the
report and is currently reviewing it. 198 Representative Maurice Hinchey,
whose office released the report, stated, "[t]he case demonstrates the
need for Congress to mandate the complete disclosure of all clinical
studies for FDA-approved drugs so that patients and their doctors, not the
drug companies, decide whether benefits of taking a certain medicine
outweigh the risks." 199 The author of the Eli Lilly report, Dr. Charles
Beasley, responded by stating "the data were reviewed extensively at the
time, but we did not believe this data, for a number of reasons, were
terribly useful or informative in terms of suggesting anything about a
causal link between the drug and the adverse effects being reported.
200
Plaintiffs can now combine the released internal documents and the
new black box warnings with the strategies employed by the Tobin
attorneys, all of which might increase the rate of success against SSRI
manufacturers. Andy Vickery, the Tobin lead attorney, credits two
193. Id.
194. Id.
195. Id.
196. Id.
197. Id.
198. Id.
199. Id.
200. CNN.com, Documents: Prozac Use Reports More Likely To List Suicide, Jan.
4, 2005, http://www.cnn.com/2005/HEALTH/01/04/prozac.documents/.
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strategies for his success. 20 First, Vickery did not let the case be
narrowed down by the defense to whether Paxil caused the killings or
depression.2 °2 Secondly, Vickery credits the ultimate success of his case
to his discovery of negative internal GlaxoSmithKline documents, which
he used to show the company's knowledge of harmful side effects.20 3
Vickery's first strategy was a success since he conceded that depression
places people at risk for suicide, but argued that scientific testimony from
experts would show that there could have been "a biological trigger that
was a concurrent cause of the tragedy. 20 4 The mandatory black box
warnings could change the minds of those who are still skeptical that an
antidepressant drug and not depression was the cause of violent and
suicidal behavior.
Vickery also argued that Glaxo was aware of Paxil's potential for
causing extreme reactions and the company should have conducted more
testing before releasing it to the public.0 5 Vickery's claim was
supported by internal documents from Glaxo of studies that showed
hundreds of volunteers had negative reactions to Paxil, including
attempted suicide.20 6 If potential plaintiffs follow the strategy employed
by Vickery, and use the black box warnings and released internal
documents as evidence, they should be increasingly successful because
there is even more evidence against manufacturers than was available in
the Tobin case.
V. Conclusion: Future Dilemmas and Implications from SSRI Litigation
In light of the many new lawsuits involving SSRI drugs, the medical
community and the pharmaceutical industry will face several dilemmas
in the future. First, doctors will have to adjust how they treat and
monitor their patients taking SSRI drugs. They will have to alert patients
and parents of the black box warnings on the drugs and advise them on
how to watch for warning signs of suicide in their children. Even before
the black box warnings were ordered, some statistics showed that
physicians had already begun to decrease prescriptions of SSRI drugs to
201. Holt, supra note 4, at 85.
202. Id.
203. Id. at 86.
204. Id. at 84.
205. Id. at 86.
206. Id. at 86.
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teens and children.2 °7 One such study, released by Medco Health
Solutions, a leading pharmacy benefit manager, surveyed the impact that
the FDA's October 2003 Public Health Advisory had on physicians.20 8
Medco's survey revealed that there was nearly a 12% decrease in the
number of children and teen patients on an SSRI drug in the second
quarter of 2004 and an overall 5% decrease in the entire state of
Illinois. 20 9 The chief medical officer of Medco stated:
The research shows that physicians and parents in Chicago and across the
state are beginning to respond to the growing evidence that antidepressants
need to be used with caution when treating children for depression. While
antidepressants have very effectively treated many children suffering from
depression, studies show that greater caution is needed when treating
pediatric and teen depression with medication, and it is clear that
210physicians are heeding these warnings.
Although the black box warnings are only for children and teens,
adult prescriptions could be targeted next since the exposure of the
documents showing manufacturers' knowledge of a link between suicide
and all patients. This will certainly effect the overall way physicians
monitor all patients on SSRIs.
Secondly, the pharmaceutical industry will be financially impacted
if they have to continue to settle and/or litigate claims by patients. In
addition, although SSRI drugs are still a billion dollar market, it is
probable that the recent negative press will impact sales and the
reputation of these companies.
Finally, although all of the measures that were taken to alert the
public on the potential ill effects of using an SSRI drug were a
tremendous triumph for patients' rights, this victory has to be balanced
by the fact that these drugs have been an effective depression
treatment. 21 1 The negative press creates hysteria for some users who
become concerned that they are in danger. The challenge facing the
FDA and other researchers is to plan how to present the data collected to
the public in order to not create panic for users, who might stop their
207. PRNewswire-FirstCall, Chicago Responds to FDA Warning on Pediatric
Antidepressants with Significant Reduction in Use, http://phx.corporateir.net
/phoenix.zhtml?c=131268&p=irol-newsArticle-print+ID=622556 (last visited Mar. 29,
2006).
208. Id.
209. Id.
210. Id.
211. See generally MSN.com, New Warning Label Ordered for Antidepressants,
Oct. 15, 2004, http://www.msnbc.msn.com/id/6254504/print/l/displaymode/1098/.
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medication or tamper with their dosages. 212 A conscious effort is needed
by those disseminating the data on the side effects to promote the
importance of allowing a physician to monitor a patient's use of drugs
and allowing only a physician to take a patient off of a drug. This
emerging area of products liability litigation will be very tricky. If a
patient who should be on an antidepressant drug, stops taking it because
of the warnings and hurts themselves or someone else, courts may place
liability with doctors for failure to monitor their patients effectively.
These are just some of the many conflicts that can potentially arise in the
future in this emerging area of the law. Because of the potential for fatal
consequences, the government must provide adequate funding for
literature and training for physicians, parents, and patients on how to best
monitor and treat depression. These steps are essential so that patients
and their loved ones can be assured that neither the depression they
suffer from, nor the SSRI drugs prescribed to help cure them, will take
their lives.
212. Id.
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